Chemomab Therapeutics Ltd (CMMB) ADR EACH REPR 20 ORD SHS SPON

Sell:$1.19Buy:$1.24$0.03 (2.50%)

Prices delayed by at least 15 minutes
Sell:$1.19
Buy:$1.24
Change:$0.03 (2.50%)
Deal now
Prices delayed by at least 15 minutes
Sell:$1.19
Buy:$1.24
Change:$0.03 (2.50%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Key people

Adi Mor
Chief Executive Officer, Director
Sigal Fattal
Chief Financial Officer
Matthew B. Frankel
Chief Medical Officer, Vice President - Drug Development
Nissim Darvish
Independent Chairman of the Board
Neil Cohen
Independent Director
Alan Charles Moses
Independent Director
Claude Nicaise
Independent Director
Click to see more

Key facts

  • EPIC
    CMMB
  • Location
    Israel
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US16385C1045
  • Market cap
    $22.26m
  • Employees
    20
  • Shares in issue
    377.13m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.